Navigation Links
Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
Date:8/2/2010

ROCKVILLE, Md., Aug. 2 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the second quarter of 2010, on Thursday, August 5, 2010, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results at 10:00 AM ET on Thursday, August 5, 2010. Also participating on the call will be Stephanie R. Irish, Acting CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.

The teleconference dial-in numbers are as follows:

Domestic callers 1-866-788-0544

International callers 1-857-350-1682

Participant Passcode 57802480

The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, August 5, 2010, beginning at 1:00 PM ET and will be accessible until Thursday, August 12, 2010, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 89391430.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:

Cristina Murphy

Communications Manager

Vanda Pharmaceuticals Inc.

(240) 599-4500

cristina.murphy@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
2. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
3. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
4. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
5. Vanda Pharmaceuticals Reports First Quarter 2009 Results
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
7. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
8. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
10. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
11. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... Rosalind™, the first-ever genomics analysis platform specifically designed for life science researchers ... honor of pioneering researcher Rosalind Franklin, who made a major contribution to ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):